Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Dr. Tudor Fulga, who will be joining Vertex Pharmaceuticals as Vice President/Head of Gene Editing and Discovery Biology.

Headshot of Tudor FulgaDr. Fulga will remain associated with our Institute as a Visiting Professor of Genome Biology until October 2021 in the first instance. During this time, Dr. Fulga will continue ongoing collaborations and mentoring his graduate students.

The transition to Vertex Pharmaceuticals constitutes an exciting career move for Dr. Fulga, who will lead the gene editing and discovery research program at the new Vertex Genetic Therapies (VGT) site in the Boston area. The relationship with Vertex was initiated by an intriguing talk at a recent Keystone Symposia:

“Earlier in the year I listened to a talk by Dr. Leonela Amoasii, a former postdoc (currently Director of Research Gene Editing at VGT) of Prof. Eric Olson at the University of Texas Southwestern Medical Centre and co-founder of Exonics Therapeutics (since acquired by Vertex Pharmaceuticals). Her talk described their fascinating work on using genome editing to restore dystrophin levels in the muscle of canine models of Duchenne Muscular Dystrophy, which was recently published in Science. This groundbreaking research and implicitly the potential of this technology in developing the first gene-editing based therapy for Duchenne were simply astonishing.”

This initial encounter was the starting point for extremely captivating discussions and a journey that culminated with Dr. Fulga’s new position at Vertex.

“For the past 8 years I had the unique opportunity to work with some of the most brilliant students, postdocs and colleagues, and I was surrounded by fantastic mentors and an extremely supportive environment. I have also been extremely fortunate to start my lab in Oxford at a time when genome editing became a game-changing platform for biomedical research. I believe that we are now on the verge of a historical moment in medicine and I look forward to joining the Vertex team and to dedicating my time to the development of transformative therapies for Duchenne Muscular Dystrophy and other devastating diseases.” 

We wish Dr. Fulga all the best in his future endeavours and his upcoming move to Boston.

Similar stories

Anjali Kusumbe receives the RMS Life Sciences Medal

The Royal Microscopical Society awards celebrate the best in microscopy, recognising those making a special contribution to microscopy, cytometry and imaging.

Wellcome Trust funding success for Jim Hughes and James Davies

£3.6 million in funding awarded by the Wellcome Trust to combine cutting-edge 3D genome technologies with machine learning approaches to decipher the role of the non-coding genome in disease.

Study of T-cell receptor activation leads to surprising discovery

A study from Davis Group is the first to describe the structure of the T-cell receptor when bound to an activating ligand. The findings shed light on an important trigger in the immune system, and suggest a completely new process by which cell receptors can be activated.

Biotech spinout MiroBio acquired by Gilead Sciences for ~£332m

Co-founded by Prof. Simon Davis, MiroBio focuses on developing therapeutics for inflammatory diseases.

Seven research groups secure LEAF Sustainability Awards

The Laboratory Efficiency Assessment Framework (LEAF) aims to support research groups to embed sustainability into their work.